Tango Therapeutics, INC. (TNGX) — SEC Filings

Q: What are the key financial highlights for Tango Therapeutics, INC.?

Key financial highlights for Tango Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Tango Therapeutics, INC.?

Key executives at Tango Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Tango Therapeutics, INC. stock?

Risk factors for Tango Therapeutics, INC. (TNGX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Tango Therapeutics, INC.?

Forward-looking statements and predictions from Tango Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Tango Therapeutics, INC.. Recent 3 filing on Apr 24, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Tango Therapeutics, INC. on SEC EDGAR

Overview

Tango Therapeutics, INC. (TNGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on Apr 24, 2026: On April 24, 2026, Tango Therapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates a change in the beneficial ownership of securities for the company, which is involved in the pharmaceutical preparations industry. The report period for this

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral. The dominant filing sentiment for Tango Therapeutics, INC. is neutral.

Filing Type Overview

Tango Therapeutics, INC. (TNGX) has filed 1 3, 1 ARS, 2 DEFA14A, 10 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G, 4 SC 13D/A, 4 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

Tango Therapeutics Files Initial Ownership Statement — 3 · Apr 24, 2026 Risk: low
On April 24, 2026, Tango Therapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates a change in the be
ARS Filing — ARS · Apr 17, 2026
Tango Therapeutics Files DEFA14A Proxy Materials — DEFA14A · Apr 17, 2026 Risk: low
Tango Therapeutics, Inc. filed a DEFA14A on April 17, 2026, related to additional definitive proxy soliciting materials. The filing includes several graphic doc
Tango Therapeutics Enters and Terminates Agreements — 8-K · Nov 21, 2025 Risk: medium
Tango Therapeutics, Inc. entered into a material definitive agreement on November 18, 2025. The company also terminated a material definitive agreement on the s
Tango Therapeutics' Cash Dips, WuXi AppTec Legislation Looms — 10-Q · Nov 4, 2025 Risk: high
Tango Therapeutics, Inc. (TNGX) reported a decrease in cash and cash equivalents to $58.338 million as of September 30, 2025, down from $69.530 million at Decem
Tango Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 24, 2025 Risk: medium
On October 23, 2025, Tango Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
Tango Therapeutics Files 8-K — 8-K · Oct 23, 2025 Risk: low
Tango Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting on its results of operations and financial condition, as well as other events and financial
Tango Therapeutics Announces CMO Departure, Director Changes — 8-K · Aug 25, 2025 Risk: medium
Tango Therapeutics, Inc. announced on August 21, 2025, the departure of its Chief Medical Officer, Dr. Barbara N. Weber. The company also reported on compensato
Tango Therapeutics' Q2 Net Loss Widens to $59.8M Amid Soaring R&D Costs — 10-Q · Aug 5, 2025 Risk: high
Tango Therapeutics, Inc. reported a net loss of $59.8 million for the quarter ended June 30, 2025, a significant increase from the $47.3 million net loss in the
Tango Therapeutics Files 8-K on Shareholder Votes and Bylaws — 8-K · Jun 6, 2025 Risk: low
Tango Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting on matters submitted to a vote of security holders and amendments to its articles of incorporat
Tango Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
Tango Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key financ
Tango Therapeutics Files Proxy Materials for 2025 Meeting — DEFA14A · Apr 22, 2025 Risk: low
Tango Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on April 22, 2025, related to its 2025 Annual Meeting. The filing indicates no
Tango Therapeutics Executive Compensation Details Released — DEF 14A · Apr 21, 2025 Risk: low
Tango Therapeutics, Inc. filed a DEF 14A on April 21, 2025, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes i
Tango Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
Tango Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly BCTG Acquisition
8-K Filing — 8-K · Jan 13, 2025
SC 13G Filing — SC 13G · Nov 20, 2024
Boxer Capital Ups Tango Therapeutics Stake to 14.9% — SC 13D/A · Nov 7, 2024 Risk: medium
Boxer Capital Management, LLC, along with related entities and individuals, has filed an amendment (Amendment No. 6) to their Schedule 13D concerning Tango Ther
Tango Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
Tango Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results, including research and development
Boxer Capital Ups Tango Therapeutics Stake — SC 13D/A · Oct 28, 2024 Risk: medium
Boxer Capital Management, LLC, along with affiliated entities, has amended its Schedule 13D filing concerning Tango Therapeutics, Inc. as of October 28, 2024. T
Boxer Asset Management Amends Tango Therapeutics Stake — SC 13D/A · Oct 15, 2024 Risk: medium
Boxer Asset Management Inc. filed an amendment (No. 4) to its Schedule 13D on October 15, 2024, regarding its holdings in Tango Therapeutics, Inc. The filing in
Third Rock Ventures Amends Tango Therapeutics Stake — SC 13D/A · Sep 4, 2024 Risk: medium
Third Rock Ventures IV, L.P. filed an amendment (No. 1) to its Schedule 13D on August 30, 2024, regarding its holdings in Tango Therapeutics, Inc. The filing in
Tango Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
Tango Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
Tango Therapeutics Files 8-K on Shareholder Votes and Financials — 8-K · Jun 6, 2024 Risk: low
Tango Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, forme
Gilead to Acquire Tango Therapeutics for $1.24B — 8-K · May 23, 2024 Risk: medium
Tango Therapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $1
Tango Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk:
Tango Therapeutics, Inc. (TNGX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Tango Therapeutics, Inc. filed a 10-Q report for the period ending
Tango Therapeutics Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 29, 2024 Risk: medium
Tango Therapeutics, Inc. (TNGX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Tango Therapeutics announced progress in clinical development
SC 13G/A Filing — SC 13G/A · Apr 8, 2024
Tango Therapeutics Files 8-K for Financials — 8-K · Mar 18, 2024 Risk: low
Tango Therapeutics, Inc. filed an 8-K on March 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
FMR LLC & Abigail Johnson Disclose 9.596% Stake in Tango Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Tango Therapeutics, Inc. As of February 9, 20
Tango Therapeutics Files 8-K on Financial Results — 8-K · Feb 7, 2024
Tango Therapeutics, Inc. filed an 8-K on February 7, 2024, to announce its results of operations and financial condition. This filing, under Item 2.02, indicate

Risk Profile

Risk Assessment: Of TNGX's 24 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Tango Therapeutics, INC.'s most recent 10-Q filing (Nov 4, 2025):

Revenue: $62,384,000
Net Income: N/A
EPS: N/A
Debt-to-Equity: 0.31
Cash Position: $58,338,000
Operating Margin: -111.3%
Total Assets: $210,136,000
Total Debt: $50,105,000

Key Executives

Gall Matthew
0001816194
Dr. Barbara N. Weber
Adam Crystal, MD, PhD
Aaron I. Davis
Josh La
Josh La Grange
Kevin Gillis
Abigail P. Johnson

Industry Context

Tango Therapeutics operates in the highly competitive precision oncology sector. This field is characterized by rapid scientific advancements, significant R&D investment, and a complex regulatory pathway. Companies in this space often rely on strategic partnerships and third-party manufacturing, facing challenges related to intellectual property, clinical trial success, and market access against established players and emerging biotechs.

Top Tags

financials (5) · 10-Q (4) · pharmaceuticals (4) · biotech (4) · filing (3) · ownership-change (3) · amendment (3) · sec-filing (2) · material-agreement (2) · Biotechnology (2)

Key Numbers

Cash and cash equivalents: $58.338M — Decreased from $69.530M at Dec 31, 2024, indicating cash burn.
Marketable securities: $94.473M — Decreased from $188.387M at Dec 31, 2024, reflecting significant liquidity reduction.
Cash runway projection: 2028 — Expected period existing funds will cover operating expenses and capital expenditures.
Expected registrational trial initiation: 2026 — Target year for TNG462 (vopimetostat) registrational trial.
Shares of common stock outstanding: 134,593,998 — As of October 28, 2025.
SEC File Number: 001-39485 — Identifies the company's filing with the SEC.
IRS Employer Identification No.: 85-1195036 — Company's tax identification number.
Filing Date: 20251023 — Date of report and earliest event
Central Index Key: 0001819133 — Company identifier
Net Loss: $59.8M — for the quarter ended June 30, 2025, widened from $47.3M in prior-year quarter
Research and Development Expense: $51.7M — for the quarter ended June 30, 2025, up from $40.8M in prior-year quarter
Collaboration Revenue: $1.2M — for the quarter ended June 30, 2025, down from $2.1M in prior-year quarter
Cash and Marketable Securities: $350.0M — as of June 30, 2025, decreased from $400.0M at December 31, 2024
Cash Burn: $50.0M — over the six months ended June 30, 2025
Reporting Period End Date: 20250331 — Indicates the end of the fiscal quarter for which financial information is reported.

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant, passive stake in Tango Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

GILD · TGTX

Frequently Asked Questions

What are the latest SEC filings for Tango Therapeutics, INC. (TNGX)?

Tango Therapeutics, INC. has 32 recent SEC filings from Feb 2024 to Apr 2026, including 10 8-K, 6 10-Q, 4 SC 13D/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of TNGX filings?

Across 32 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral. The dominant sentiment is neutral.

Where can I find Tango Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Tango Therapeutics, INC. (TNGX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Tango Therapeutics, INC.?

Key financial highlights from Tango Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for TNGX?

The investment thesis for TNGX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Tango Therapeutics, INC.?

Key executives identified across Tango Therapeutics, INC.'s filings include Gall Matthew, 0001816194, Dr. Barbara N. Weber, Adam Crystal, MD, PhD, Aaron I. Davis and 4 others.

What are the main risk factors for Tango Therapeutics, INC. stock?

Of TNGX's 24 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 10 low-risk.

What are recent predictions and forward guidance from Tango Therapeutics, INC.?

Recent forward-looking statements from Tango Therapeutics, INC. include guidance on {"claim":"FMR LLC will maintain a significant, passive stake in Tango Therapeutics for the foreseeable future.","entity".